We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DuPont Expands Bioprocessing Portfolio With New Chromatography Media
Read MoreHide Full Article
Key Takeaways
DuPont launches AmberChrom SIL silica gel to enhance peptide purification, including GLP-1 therapeutics.
Available in C8 and C18 chemistries, the new media offers high resolution, stability and scalability.
DuPont's new media integrates with existing chromatography resins to optimize purity, yield and recovery.
DuPont de Nemours, Inc. (DD - Free Report) has launched AmberChrom SIL silica gel, a new reverse-phase silica-based chromatography media designed to support the purification and manufacturing of peptide therapeutics, including glucagon-like peptide-1 (GLP-1) receptor agonists. The launch expands DuPont’s bioprocessing purification portfolio and strengthens its suitability for high-purity polishing.
Growing demand for peptide therapeutics for the treatment of diabetes, obesity and other chronic conditions is increasing the need for efficient purification technologies at a larger scale. AmberChrom SIL silica gel is designed to help biopharmaceutical manufacturers meet stringent purity requirements while maintaining high yields.
Available in C8 and C18 chemistries, the new product offers high resolution, stability and scalability for demanding peptide separations. It can be used during multiple stages of purification to address diverse impurity profiles and specific process requirements.
DuPont’s latest launch can also be integrated with its existing chromatography technologies, including AmberChrom XT, AmberChrom TQ1 and CG resins. Combining silica-based and polymeric chromatography technologies with a single purification workflow enables manufacturers to optimize purity, yield and recovery across multiple stages.
The launch reinforces DuPont’s focus on expanding its solutions to address evolving needs by offering process development and manufacturing scale-up to optimize purification workflows and achieve purity targets.
Shares of DD have lost 44.4% over the past year against the 1.2% rise of its industry.
Image Source: Zacks Investment Research
DD’s Zacks Rank & Key Picks
DDcurrently carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the Basic Materials space are Reliance, Inc. (RS - Free Report) , Cabot Corporation (CBT - Free Report) and Avient Corporation (AVNT - Free Report) .
The Zacks Consensus Estimate for RS’ 2026 earnings is pegged at $23.70 per share, indicating a 66.2% year-over-year surge. RSshares have gained 50.8% over the past year.
The Zacks Consensus Estimate for CBT’s current fiscal-year earnings is pinned at $6.35 per share. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters, with an average surprise of 4.56%. CBTshares have gained 4.2% over the past year.
The Zacks Consensus Estimate for AVNT’s 2026 earnings is pegged at $3.2 per share, indicating a year-over-year rise of 13.48%. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 3.4%.
View the Zacks #1 Rank List
Image: Bigstock
DuPont Expands Bioprocessing Portfolio With New Chromatography Media
Key Takeaways
DuPont de Nemours, Inc. (DD - Free Report) has launched AmberChrom SIL silica gel, a new reverse-phase silica-based chromatography media designed to support the purification and manufacturing of peptide therapeutics, including glucagon-like peptide-1 (GLP-1) receptor agonists. The launch expands DuPont’s bioprocessing purification portfolio and strengthens its suitability for high-purity polishing.
Growing demand for peptide therapeutics for the treatment of diabetes, obesity and other chronic conditions is increasing the need for efficient purification technologies at a larger scale. AmberChrom SIL silica gel is designed to help biopharmaceutical manufacturers meet stringent purity requirements while maintaining high yields.
Available in C8 and C18 chemistries, the new product offers high resolution, stability and scalability for demanding peptide separations. It can be used during multiple stages of purification to address diverse impurity profiles and specific process requirements.
DuPont’s latest launch can also be integrated with its existing chromatography technologies, including AmberChrom XT, AmberChrom TQ1 and CG resins. Combining silica-based and polymeric chromatography technologies with a single purification workflow enables manufacturers to optimize purity, yield and recovery across multiple stages.
The launch reinforces DuPont’s focus on expanding its solutions to address evolving needs by offering process development and manufacturing scale-up to optimize purification workflows and achieve purity targets.
Shares of DD have lost 44.4% over the past year against the 1.2% rise of its industry.
Image Source: Zacks Investment Research
DD’s Zacks Rank & Key Picks
DDcurrently carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the Basic Materials space are Reliance, Inc. (RS - Free Report) , Cabot Corporation (CBT - Free Report) and Avient Corporation (AVNT - Free Report) .
RS currently sports a Zacks Rank #1 (Strong Buy), while CBT and AVNT carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here
The Zacks Consensus Estimate for RS’ 2026 earnings is pegged at $23.70 per share, indicating a 66.2% year-over-year surge. RSshares have gained 50.8% over the past year.
The Zacks Consensus Estimate for CBT’s current fiscal-year earnings is pinned at $6.35 per share. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters, with an average surprise of 4.56%. CBTshares have gained 4.2% over the past year.
The Zacks Consensus Estimate for AVNT’s 2026 earnings is pegged at $3.2 per share, indicating a year-over-year rise of 13.48%. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 3.4%.